Generic Threat

Gopal,Kevin;

Article

Pharmaceutical Executive

July 1, 2001

Pharmaceutical Executive

Pharmaceutical Executive-07-01-2001

Volume0

Issue 0

Generic Threat

Author(s):

Kevin Gopal

Epsom, Surrey, United Kingdom—Pharmaceutical companies struggle to be taken seriously when they talk of facing pressures. A quick look at the bottom line often suggests they are overstating their worries. But new evidence shows they are being squeezed by generic competition and falling R&D output.

Articles in this issue

Pharmacies: OTC Price Wars

One Disease at a Time

Overview of the Industry: A World of Opportunities

The Power Shift

A Giant Stumbles

Overruled: No More Dual Pricing

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Generic Threat

Newsletter